User:Raia Hasan/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 64: | Line 64: | ||
Consists of a <scene name='90/909933/Light_chain/2'>heavy chain (100 kDa) and light chain(50 kDa)</scene> which are linked together by a single disulfide bond. It is a 150- kDa molecular weight protein that inhibits the release of acetylcholine by blocking the neuromuscular communications and transmissions on motor and sympathetic nerve terminals. The heavy chain binds at the pre-synaptic surface of cholinergic neurons. They bind one way and are irreversible. Endocytosis allows for the toxin receptor- complex to be sent into the cell after binding. The botulism toxin enters the cytoplasm after the disulfide bond between the two chains is broken. The light chain interacts with SNAP-25 (needed for binding/ attachment and release of ACH from vesicles) specifically at the nerve terminal to prevent binding of acetylcholine vesicles with the cell membrane. | Consists of a <scene name='90/909933/Light_chain/2'>heavy chain (100 kDa) and light chain(50 kDa)</scene> which are linked together by a single disulfide bond. It is a 150- kDa molecular weight protein that inhibits the release of acetylcholine by blocking the neuromuscular communications and transmissions on motor and sympathetic nerve terminals. The heavy chain binds at the pre-synaptic surface of cholinergic neurons. They bind one way and are irreversible. Endocytosis allows for the toxin receptor- complex to be sent into the cell after binding. The botulism toxin enters the cytoplasm after the disulfide bond between the two chains is broken. The light chain interacts with SNAP-25 (needed for binding/ attachment and release of ACH from vesicles) specifically at the nerve terminal to prevent binding of acetylcholine vesicles with the cell membrane. | ||
| - | "Botulinum toxin is a<scene name='90/909933/Zinc/5'> zinc-dependent endoprotease</scene> that acts on vulnerable cells to cleave polypeptides that are essential for exocytosis"<ref name=zinc>Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200</ref> | + | "Botulinum toxin is a <scene name='90/909933/Zinc/5'>zinc-dependent endoprotease</scene> that acts on vulnerable cells to cleave polypeptides that are essential for exocytosis"<ref name=zinc>Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc-binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200</ref> |
| - | Botulinum toxin Type 1 or Botox contains two modules: the | + | Botulinum toxin Type 1 or Botox contains two modules: the <scene name='90/909933/N-term/2'>N-terminal translocation domain</scene> (residues 441-875, in salmon) and the C-terminal receptor-binding domain (<scene name='90/909933/C-term/1'>residues 876-1296</scene>)<ref name=domains>Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898-902.</ref> |
Revision as of 18:38, 2 May 2022
Botulinum Neurotoxin
| |||||||||||
References
- ↑ Lakna. (2018, July 16). Difference between spore-forming bacteria and non-spore-forming bacteria. Pediaa.Com. Retrieved April 27, 2022
- ↑ Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]
- ↑ Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution [Link]https://pediaa.com/difference-between-spore-forming-bacteria-and-non-spore-forming-bacteria
- ↑ Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0
- ↑ Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015
- ↑ 6.0 6.1 6.2 6.3 World Health Organization. (2018, January 10). Botulism. World Health Organization. Retrieved May 2, 2022, from https://www.who.int/news-room/fact-sheets/detail/botulism
- ↑ Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123
- ↑ Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594
- ↑ How botox® is injected. The Cosmetic Skin Clinic. (2021, November 2). Retrieved April 27, 2022, from https://www.cosmeticskinclinic.com/advice-centre/how-botox-is-injected
- ↑ Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc-binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200
- ↑ Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898-902.
